Home > IDO & > Indoximod

Indoximod

1-甲基-D-色氨酸,NLG-8189,1-Methyl-D-tryptophan,NLG 8189,NLG8189,

Indoximod是一种IDO抑制剂, 并逆转IDO介导的免疫抑制。

目录号
EY1295
EY1295
纯度
99.58%
99.58%
规格
50 mg
100 mg
原价
200
300
售价
200
300
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Indoximod (NLG-8189), a methylated tryptophan, acts as an IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, and reverses IDO-mediated immune suppression. Phase 2.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

    400 mg/kgp.o.

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Hou DY, et al. Cancer Res. 2007, 67(2), 792-801.

    分子式
    C12H14N2O2    		 分子量
    218.25    		 CAS号
    110117-83-4    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    5 mM    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00739609 Breast Cancer|Lung Cancer|Melanoma|Pancreatic Cancer|Solid Tumors Drug: 1-methyl-D-tryptophan NewLink Genetics Corporation Phase 1 2008-08-01 2015-05-29
    NCT01560923 Metastatic Prostate Cancer Biological: Indoximod|Biological: Sipuleucel-T|Other: Placebo Masonic Cancer Center, University of Minnesota Phase 2 2012-10-01 2016-11-07
    NCT02835729 Acute Myeloid Leukemia Drug: Idarubicin|Drug: Cytarabine|Drug: Indoximod|Other: Placebo NewLink Genetics Corporation Phase 1|Phase 2 2016-07-01 2016-08-10
    NCT02502708 Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor|Ependymoma|Medulloblastoma Drug: Indoximod|Drug: Temozolomide|Radiation: Conformal Radiation NewLink Genetics Corporation Phase 1 2015-10-01 2017-01-09
    NCT02077881 Metastatic Pancreatic Adenocarcinoma|Metastatic Pancreatic Cancer Drug: Nab-Paclitaxel|Drug: Gemcitabine|Drug: Indoximod NewLink Genetics Corporation Phase 1|Phase 2 2014-08-01 2016-04-25
    NCT00567931 Unspecified Adult Solid Tumor, Protocol Specific Drug: 1-methyl-d-tryptophan|Other: pharmacological study|Other: laboratory biomarker analysis National Cancer Institute (NCI) Phase 1 2007-10-01 2014-07-23
    NCT01042535 Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Unspecified Adult Solid Tumor, Protocol Specific Biological: adenovirus-p53 transduced dendritic cell (DC) vaccine|Drug: 1-methyl-d-tryptophan|Other: Laboratory biomarker analysis H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) Phase 1|Phase 2 2009-12-01 2016-11-01
    NCT02073123 Metastatic Melanoma|Stage III Melanoma|Stage IV Melanoma Drug: Indoximod|Drug: Ipilimumab|Drug: Nivolumab|Drug: Pembrolizumab NewLink Genetics Corporation Phase 1|Phase 2 2014-07-01 2016-03-22
    NCT01792050 Metastatic Breast Cancer Drug: Docetaxel|Other: Placebo|Drug: Indoximod|Drug: Paclitaxel NewLink Genetics Corporation Phase 2 2013-02-01 2016-03-14
    NCT01191216 Unspecified Adult Solid Tumor, Protocol Specific Drug: 1-methyl-d-tryptophan|Drug: docetaxel|Other: diagnostic laboratory biomarker analysis|Other: pharmacological study National Cancer Institute (NCI) Phase 1 2010-09-01 2014-07-23
    NCT02460367 Non-small Cell Lung Cancer|Progression of Non-small Cell Lung Cancer|Non-small Cell Lung Cancer Recurrent Drug: Docetaxel|Biological: Tergenpumatucel-L|Drug: Indoximod 600mg|Drug: Indoximod 1200mg NewLink Genetics Corporation Phase 1|Phase 2 2016-01-01 2016-02-02
    NCT02052648 Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor Drug: Indoximod|Drug: Temozolomide|Drug: Bevacizumab|Radiation: Stereotactic Radiation NewLink Genetics Corporation Phase 1|Phase 2 2014-03-01 2016-11-02
    NCT01302821 Breast Cancer Biological: Adenovirus-p53 transduced dendritic cell vaccine|Drug: 1-methyl-D-tryptophan|Radiation: Carbon C 11 alpha-methyltryptophan H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) 2013-01-01 2017-02-21
    NCT02913430 Metastatic Breast Cancer Drug: Fulvestrant|Drug: Tamoxifen University of Pittsburgh Phase 2 2016-10-01 2016-10-31

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：